Home monitoring for pediatric persistent asthma

Persistent asthma in children is a chronic condition managed against a physician-authored action plan, with daily controller medication and periodic reassessment as the guideline standard. This domain holds context on how large the persistent (not just "current") pediatric asthma population is, what home spirometry/peak-flow devices already exist and how crowded that hardware market already is, what CMS actually pays for RPM billing in CY2026, and what happened to the small number of US/industry-sponsored pediatric home-RPM-asthma-monitoring research programs that have actually been attempted. Expect this file to be thin on care pathway and user-group detail (not deeply searched this pass) and to carry an unresolved gap on commercial/Medicaid coverage policy specifically for pediatric RPM — that thinness is stated in each section rather than papered over.

This file carries no confidence tags. Every line below is context with a source attached. To affect a score, a line must be copied into a candidate's ## Claims as unverified and pass the Verifier or the Corroborator. See README.md in this directory.

1. Condition & epidemiology

as_of: 2026-08-31 · sources searched: connectors literature (multiple queries), literature-detail on PMID 39025120, 39052508, 39298796; WebFetch of archive.cdc.gov/www_cdc_gov/asthma/asthma_stats/severity_child.htm · not searched: state-level or metro-level prevalence, incidence (new diagnoses/year), a persistent-asthma absolute headcount (only percentages were located, see Gaps)

Verbatim, load-bearing:

"Intermittent severity includes people who are well-controlled without long-term control medication... Persistent severity includes people who are on long-term control medications and people with uncontrolled asthma (not well-controlled or very poorly controlled) who are not on long-term control medication." — [2]

"Prevalence of current asthma was higher among non-Hispanic Black people (children, 12.5%; adjusted prevalence ratio [APR] = 2.19; 95% CI, 1.68-2.84... ) compared with non-Hispanic White people (children, 5.7%...)." — [1]

This is the single most useful correction this dossier makes to the candidate's own epidemiology claim. idea-014's claim 9 assumes, unsourced, that persistent asthma is "roughly 30-40%" of the pediatric current-asthma population. The one primary figure located this pass — [2], admittedly dated (BRFSS 2006-2010, not the NHIS 2023 vintage the candidate's own claim 7 cites for the denominator) — puts persistent asthma at a majority, 60.3%, of children with current asthma, not a minority. The two figures are not directly comparable (different survey, different decade) but the direction of the gap is large enough that it should not be treated as a rounding difference; either update the addressable-share estimate or explicitly flag why a 15-20-year-old BRFSS figure is being set aside.

Gaps: The specific "4.8 million children / 6.7% / 2023" current-asthma figure that idea-014's claim 7 cites (attributed there to "CDC data reported via web search") could not be independently retrieved by this dossier pass — cdc.gov/asthma-data/about/, cdc.gov/nchs/fastats/asthma.htm, and cdc.gov/pcd/issues/2024/24_0005.htm all returned HTTP 403 to both WebFetch and a direct curl with a browser user-agent, and archive.cdc.gov's mirror of the most-recent-asthma-data page returned HTTP 404. cdc.gov gates intermittently, the same class of hazard docs/backlog.md 1.6 already documents for fda.gov — recorded here explicitly because it was not previously documented for cdc.gov in this repo. archive.cdc.gov worked for the severity page ([2]) but not for the current-asthma prevalence page. This is not retrieved, not not found — the figure may well be correct, it simply could not be checked from here this pass. No absolute headcount for persistent pediatric asthma specifically (as opposed to a percentage) was located by anyone. Incidence and state/metro-level concentration were not searched.

2. Care pathway & clinical setting

as_of: 2026-08-31 — not searched this pass. No literature or web query targeted the referral pathway (who orders spirometry, where the action plan is written, follow-up cadence) for pediatric persistent asthma specifically. What is visible from sections 4-5 below: care is delivered in outpatient pediatric, allergy, or pulmonology clinics, with the physician authoring an asthma action plan against which home readings are compared.

Gaps: the entire section — referral pattern, visit cadence, action-plan authorship workflow, and site-of-service detail were not searched.

3. User groups & incentives

as_of: 2026-08-31 — not deeply searched. Roles below are inferred from sections 1, 5 and 6 rather than from a dedicated search.

Gaps: almost the entire section. The payer row's Medicaid/commercial (not Medicare) framing is a structural inference from population age, not a sourced finding — it should be read as a flag for what needs sourcing, not as an established fact.

4. Standard of care & clinical evidence

as_of: 2026-08-31 · sources searched: connectors literature, literature-detail on PMID 31810411, 38742250 · not searched: the NAEPP/NHLBI EPR-3 guideline text itself (not fetched directly this pass; its severity-classification language is inferred from [2]'s restatement of it)

Verbatim, load-bearing:

"Lung function measurements from the VitalFlo mobile spirometer were comparable to a commercially-available spirometer commonly used in clinical settings... This validated app-based spirometer for home use has the potential to improve asthma self-management." — [5], Journal of Asthma, 2021, n=48 adolescents, FEV1 r²=0.721 (95% CI 0.749±0.120, P<.001), mean FEV1 difference 0.00764 L (P=.87), Bland-Altman showed no significant bias

"Specific technologies for preschool children represent a gap in the literature that needs to be specifically addressed in future research." — [6]

Read this narrowly. [5] validates one specific commercial spirometer (VitalFlo, not any device named in idea-014) against one clinic-grade comparator in a single US academic clinic's adolescent population — it is favorable evidence that home electronic spirometry can be accurate in this age range, not evidence that this candidate's specific hardware is. [6] establishes that pediatric telemonitoring for asthma is an active, populated research area (40 technologies) rather than a novel concept, which cuts toward the candidate's own "differentiation is billing/indication scope, not hardware" self-assessment.

Gaps: No guideline-level (NAEPP/EPR-3, GINA) primary text was fetched this pass — the persistent/intermittent severity definitions used throughout this dossier are taken from [2]'s restatement, not the guideline document itself. No pediatric-specific accuracy/false-alert-rate study (as opposed to a correlation/validation study) for a peak-flow-only device (as opposed to full spirometry) was located.

5. Reference products — and why people stop using them

as_of: 2026-08-31 · sources searched: connectors clearances/classification/recalls (product codes BZG, BZH), connectors trials, trial-detail on 3 NCTs, connectors literature · not searched: MAUDE (no connector in this repo — docs/backlog.md 1.9), device-level pricing, any patient-level (as opposed to study/program-level) adherence or dropout cohort for home peak-flow/spirometry monitoring specifically (searched directly this pass under two different query phrasings and returned zero PubMed records for both — see below)

In-clinic spirometry / periodic action-plan review — the incumbent standard, not a device

• What it is: Physician-ordered spirometry performed at scheduled visits, against which an asthma action plan is written and periodically revised. Not a single cleared product; the default pathway a home-monitoring device would supplement or partially substitute.
• Abandonment record — why people stop: Not established this pass. Two distinct query phrasings — "peak flow meter adherence discontinuation asthma children" and "symptom diary adherence pediatric asthma home monitoring dropout" — each returned zero PubMed records. This is recorded as not found, not merely not searched: a patient-level adherence or dropout cohort study for pediatric peak-flow/spirometry self-monitoring specifically was searched for directly and did not surface. This is the single largest gap in this dossier, and it sits exactly where the candidate's desirability case would need to stand — see §9.

Connected/electronic peak-flow and spirometer hardware — a crowded, largely commodity market

• Product code BZG (diagnostic spirometer, 21 CFR 868.1840): Class II, confirmed directly via connectors classification. 24 distinct 510(k) clearances in the 2016-2026 window (a substantially larger count than the 4-5 devices idea-014's own claim 10 names), including MESI mTABLET SPIRO (K251777, 2026), Nuvoair Air Next (K231416, 2024), ndd Medizintechnik EasyOne Sky (K230178, 2023), Mir Medical Spirobank Oxi (K230501, 2023), Feellife Health Air Smart Extra (K222443, 2023), Inofab SpiroHome (K213754, 2023), and the candidate's own predicate Asthma Monitor AM3 (K183479, 2019), among 17 others. — [7]
• Product code BZH (peak flow meter, 21 CFR 868.1860): Class II, confirmed directly. 14 distinct 510(k) clearances in the 2016-2026 window, including Microlife Digital Peak Flow Meter (K253180, 2026), Shenzhen Bi-Rich (K252802, 2026), Knox Medical Aluna/Aluna 2 (K193311/K232588), Taian Dalu (K230423), Shanghai Sonmol (K203196), Safey (K200832), and Mir Medical Smart One (K181666), among others. — [8]
• Recall history: One recall in the BZG product code in this window: Z-0324-2025, Baxter Healthcare/Hillrom Welch Allyn Diagnostic Cardiology Suite (includes a diagnostic spirometry component), status Open/Classified, initiated 2024-10-11 — a software defect causing duplicate DICOM Unique Identifiers, which could mismatch a patient's identity with their physiologic data. Not related to K183479 or any device named in idea-014. **No recalls found in product code BZH** in this window. — [9]

Read this as a moat/competitive-intensity finding, not a demand finding. The sheer count of clearances (24 + 14 = 38 across the two relevant product codes in ten years, most from small OEM or single-product manufacturers) directly reinforces idea-014's own Moat/ Competitive-intensity self-assessment (2/5, "the differentiation is a billing/indication lever, not a technical one") — this is now sourced independently of the candidate's own narrower 5-device count, not merely repeated from it.

Pediatric home-RPM-asthma-monitoring research programs that have actually been attempted

This is the closest thing to a revealed-behaviour twin this dossier could find for idea-014's claim 13 (an unsourced assumption about prescriber willingness) — not what clinicians say they would do, but what happened to the specific research/pilot programs that were actually stood up:

• **ALPACA study (NCT05517096, "AmbuLatory Pediatric Asthma CAre"), sponsor Philips Electronics Nederland B.V.** — an interventional RCT of eHealth remote monitoring (spirometry, pulse oximetry, medication-adherence tracking) plus teleconsultation for children aged 4-11 with moderate-to-severe asthma. **Status: WITHDRAWN, 0 participants enrolled.** whyStopped (verbatim, ClinicalTrials.gov): "refocus of business." — [10]. Note: this trial's population was Dutch (non-US), flagged as such; the finding itself — an industry sponsor pulling out of a pediatric home-asthma-RPM study before enrolling anyone, for a stated business reason unrelated to safety or efficacy — is a market-behaviour signal, not a US clinical finding.
• **"Evaluation of a Remote Asthma Monitoring Program to Improve Health Outcomes in Pediatric Asthma" (NCT05139485), sponsor Weill Medical College of Cornell University, US.** An observational pilot of remote medication monitoring plus home visits and asthma education, ages 3-21, explicit inclusion criterion "Diagnosis of persistent asthma (mild, moderate, severe)." Status: TERMINATED after enrolling 12 (actual) participants. whyStopped (verbatim): "Staffing issues with partner site." — [11]
• **"AeviceMD for Pediatric Asthma Management" (NCT06321471), sponsor an individual investigator, US.** A single-group pilot of a wearable remote auscultation/monitoring device, ages 3-18, poorly-controlled asthma. Status: ACTIVE_NOT_RECRUITING, enrollment target 20 (ESTIMATED — a registered target, not a completed count). No results posted. — [12]

Verbatim:

"whyStopped: refocus of business" — [10], ClinicalTrials.gov NCT05517096

"whyStopped: Staffing issues with partner site." — [11], ClinicalTrials.gov NCT05139485

Read this narrowly and honestly. Neither withdrawal/termination reason is a clinical or efficacy failure — one is explicitly a sponsor business-strategy decision, the other an operational staffing problem at a partner site, not a finding that families or clinicians rejected the monitoring itself. But both are real, and both are the closest evidence this dossier could find to what actually happens when someone tries to stand up exactly this kind of program in the US pediatric asthma population: of three identified pediatric home-RPM- asthma-monitoring research efforts registered on ClinicalTrials.gov, two ended before producing outcome data and the third has not yet reported. This is offered as a caution against over-reading operational fragility in this space, not as a claim that the underlying device concept doesn't work — the two reasons given are explicitly not about the device or about patient/clinician rejection.

Gaps: No patient-level adherence/dropout cohort for home peak-flow/spirometry monitoring was found (searched directly, see above). No pricing information for any device named above was located. MAUDE complaint data is unreachable (no connector). Whether any of the 38 clearances above carry a pediatric-specific or Rx-only indication (as opposed to general/adult labeling) was not independently re-verified here beyond what idea-014's own Verifier pass already established for K183479 and K200832 specifically.

6. Reimbursement landscape

as_of: 2026-08-31 · sources searched: CMS PFS National Payment Amount File (fetched directly, see below), cms.gov/medicare/coverage/telehealth/remote-patient-monitoring (fetched directly), connectors policy against Federal Register document 2025-19787 (CY2026 PFS Final Rule), a Cigna commercial RPM/RTM coverage policy PDF (attempted) · not searched: any state Medicaid RPM policy, any other named commercial payer besides Cigna

CMS CY2026 Physician Fee Schedule payment amounts for the three RPM codes — retrieved directly from CMS's own published file, not a vendor blog. CMS's PFS National Payment Amount File (initial CY2026 release, revision PFREV26A, updated 2025-12-29, downloaded from https://www.cms.gov/files/zip/pfrev26a-updated-12-29-2025.zip) contains one row per (carrier, locality, HCPCS code) combination — 109 Medicare payment localities per code in this file. There is no single "national unadjusted" figure in this file — every row is locality-specific — so the range/mean/median below is reported instead of a single point estimate, which is a more accurate representation of what CMS actually pays than any single number:

Source: [13]. This directly supersedes the vendor-blog-sourced approximate figures (~$21.71/$47/$52) that idea-014's claims 4-6 flagged as unconfirmed — those approximate figures turn out to be within, but not identical to, the real CMS range; the vendor figures appear to be single-locality or averaged estimates, not sourced or labeled as such by the vendors who published them.

This repo's own data/hcpcs_payment_rates.csv cache remains unpopulated — this dossier pass retrieved and computed the figures above by hand from the raw CMS file rather than writing them into the shared cache, because the cache's schema (code, schedule, payment_rate, year) expects a single national-unadjusted rate per code, and computing that correctly requires the companion RVU/GPCI file (not the payment-amount file used here) — attempting that arithmetic without it risked writing an incorrect number into a file every future candidate's payment connector call would trust. That remains open work, named in §9.

CMS RPM eligibility criteria, verbatim from CMS's own page (not a vendor summary):

"To be eligible for remote patient monitoring, a patient must: - Have a chronic or acute condition that requires monitoring - Use an internet-connected device that: o Meets that FDA's definition of a medical device and digitally uploads data o Collects and transmits health data at least 2 days every 30 days" — [14], cms.gov/medicare/coverage/telehealth/ remote-patient-monitoring, page last modified 2026-05-13

This is a materially different — broader — eligibility bar than idea-014's claim 11 assumed. Claim 11 frames the requirement as the device being used "in the management of a chronic or acute condition" — CMS's own current page says exactly that ("chronic or acute condition"), not chronic-only as the candidate's narrower framing implied. This does not resolve the candidate's underlying regulatory-preamble sourcing gap (this page is CMS's public consumer/provider-facing summary, not the PFS final-rule preamble itself), but it is a real, directly-quoted CMS source stating the criterion in CMS's own words, which the candidate file did not have.

Federal Register CY2026 PFS Final Rule (document 2025-19787, 90 FR 49266) was confirmed to discuss RPM and to name CPT 99453/99454/99457 directly — connectors policy verified the phrases "remote physiologic monitoring," "99454," "99457," and "conversion factor" are present in the document's own text. This connector confirms phrase presence and returns only a short context window around each match — it cannot extract the rule's full RVU-impact tables, so the specific dollar values above come from the CMS payment-amount file, not this connector call. — [15]

Coverage policy: No Medicare NCD or LCD specifically naming pediatric asthma RPM was located. A named commercial policy exists — Cigna, "Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM)," policy MM_0563 — but its text could not be read in this environment: the PDF was downloaded successfully (334.9 KB, HTTP 200) but this environment has neither pypdf nor pdftotext installed, the same missing-dependency limitation already documented in this repo's pediatric-obstructive-sleep-apnea-testing.md dossier for a different PDF. Recorded as not retrieved, with a real, resolvable identifier for a later pass to pick up — [16].

Gaps: No state Medicaid RPM/asthma policy was searched. No commercial payer besides Cigna was checked, and Cigna's own policy text remains unread. The payer-of-record question from §3 (Medicaid/CHIP/commercial, not Medicare, for this age group) is unresolved by this section — CMS's national payment amounts function as a reference point other payers commonly anchor to, not as evidence that any specific payer covers this indication.

7. Technology trajectory

as_of: 2026-08-31 — derived entirely from the §5 clearance sweep, not an independent search. Connected/Bluetooth spirometry and peak-flow hardware has clearly proliferated over the last decade (38 clearances across BZG+BZH in 2016-2026, arriving at a rate of roughly 3-4 per year each), moving from single-purpose mechanical peak-flow meters toward app-paired electronic spirometers with cloud data transmission — consistent with what would be needed as the hardware substrate for an RPM-billed product, though none of the clearances found carry an RPM-specific or prescription-only indication on their face (unconfirmed beyond what idea-014 itself already established for K183479/K200832). Note that a counted series (clearances per year) cannot itself carry a confidence tag in this repo (docs/backlog.md 1.10) and is recorded here as context only, not as a scoreable finding.

Gaps: No sensor-level, cost, or miniaturization trend was independently searched — the table above is inferred from clearance counts alone, not a technology-history literature search.

8. Market players & dynamics

as_of: 2026-08-31 · sources searched: the same BZG/BZH clearances/recalls sweep as §5, plus the three NCT records already retrieved · not searched: funding rounds, company launches/exits, or acquisition activity specific to a pediatric-asthma-RPM market segment

Gaps: No funding, acquisition, or company-exit data specific to a pediatric-asthma-RPM market segment (as opposed to the regulatory clearance roster and the two study terminations already documented) was searched.

9. Open questions — and what would settle them

Class-3 questions above are recorded, never answered, and paired with their nearest revealed-behaviour twin per docs/research-lane-spec.md §3.1.

10. Provenance & staleness

What this dossier has never looked at: care pathway and user-group detail beyond inference (§2/§3 in full); the NAEPP/EPR-3 guideline's own text; any state Medicaid or non-Cigna commercial coverage policy; the true GPCI-adjusted national CMS payment figure (the locality range in §6 is real CMS data, not a substitute for that computation); MAUDE device-complaint data (no connector exists in this repo for it); and funding/market-dynamics data specific to this segment as opposed to what a regulatory-clearance and trial-registry sweep incidentally surfaced. A later pass with a working pypdf/pdftotext install, the companion CMS RVU/GPCI file, and a state-Medicaid coverage search would close the largest remaining gaps without needing new literature.

Sources

1. PMID 39025120 — "The Status of Asthma in the United States," Preventing Chronic Disease, 2024-07-18 (NHIS 2010-2021, NEDS/NIS/HCUP/AHRQ, NVSS 2010-2021).
2. CDC, "Asthma Severity Among Children with Current Asthma" (https://archive.cdc.gov/www_cdc_gov/asthma/asthma_stats/severity_child.htm), citing the BRFSS Adult Asthma Call-back Survey, 2006-2010, 35 states + DC — retrieved via WebFetch, 2026-08-31.
3. PMID 39052508 — "Sociodemographic Factors of Asthma Prevalence and Costs Among Children and Adolescents in the United States, 2016-2021," Preventing Chronic Disease, 2024-07-25 (2016-2021 Medical Expenditure Panel Survey, n=2,365 treated / 40,497 untreated).
4. PMID 39298796 — "Trends in US Pediatric Asthma Hospitalizations, by Race and Ethnicity, 2012-2020," Preventing Chronic Disease, 2024-09-19 (2012-2020 National Inpatient Sample).
5. PMID 31810411 — "Validation of an app-based portable spirometer in adolescents with asthma," The Journal of Asthma, 2021 (n=48 adolescents, University of North Carolina).
6. PMID 38742250 — "Telemonitoring of pediatric asthma in outpatient settings: A systematic review," Pediatric Pulmonology, 2024 (40 studies through Sept 2023).
7. openFDA device/510k clearances, product_code=BZG, 2016-09-02 to 2026-08-31 (24 records) — python3 -m connectors clearances --product-code BZG --since 10y; openFDA device/classification product_code=BZG (Class 2, Spirometer Diagnostic, regulation 868.1840) — python3 -m connectors classification --product-code BZG.
8. openFDA device/510k clearances, product_code=BZH, 2016-09-02 to 2026-08-31 (14 records) — python3 -m connectors clearances --product-code BZH --since 10y; openFDA device/classification product_code=BZH (Class 2, Meter Peak Flow Spirometry, regulation 868.1860) — python3 -m connectors classification --product-code BZH.
9. openFDA device/recall, product_res_number=Z-0324-2025 — Baxter Healthcare Corporation / Hillrom Welch Allyn Diagnostic Cardiology Suite, status Open/Classified, initiated 2024-10-11, related 510(k) K191013, product_code BZG.
10. ClinicalTrials.gov NCTId=NCT05517096 — "AmbuLatory Pediatric Asthma CAre" (ALPACA), sponsor Philips Electronics Nederland B.V., status WITHDRAWN, enrollment 0 (ACTUAL), whyStopped "refocus of business."
11. ClinicalTrials.gov NCTId=NCT05139485 — "Evaluation of a Remote Asthma Monitoring Program to Improve Health Outcomes in Pediatric Asthma," sponsor Weill Medical College of Cornell University, status TERMINATED, enrollment 12 (ACTUAL), whyStopped "Staffing issues with partner site."
12. ClinicalTrials.gov NCTId=NCT06321471 — "AeviceMD for Pediatric Asthma Management," sponsor Irina Dralyuk, status ACTIVE_NOT_RECRUITING, enrollment 20 (ESTIMATED), hasResults=false.
13. CMS PFS National Payment Amount File, revision PFREV26A (initial CY2026 release, updated 2025-12-29) — https://www.cms.gov/files/zip/pfrev26a-updated-12-29-2025.zip, file PFALL26AR.txt, CPT codes 99453/99454/99457, all 109 Medicare payment localities, non-facility and facility fee schedule amount fields — downloaded and parsed directly, 2026-08-31.
14. cms.gov, "Remote Patient Monitoring" (https://www.cms.gov/medicare/coverage/telehealth/remote-patient-monitoring), page last modified 2026-05-13 — retrieved via direct fetch, 2026-08-31 (WebFetch tool returned HTTP 403; a direct curl with a browser user-agent returned HTTP 200).
15. Federal Register, document_number=2025-19787 (90 FR 49266) — "Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule..." — phrase presence for "remote physiologic monitoring," "99454," "99457," "conversion factor" confirmed via python3 -m connectors policy 2025-19787 --expect-type final-rule.
16. Cigna, "Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM)," policy MM_0563 (https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0563_coveragepositioncriteria_remote_patient_monitoring_and_remote_therapeutic_monitoring.pdf) — downloaded successfully (334.9 KB, HTTP 200) but not retrieved as text: this environment has neither pypdf nor pdftotext installed.